Barclays' $25 Target: Assessing Hims & Hers' Post-GLP-1 Structural Pivot

The core story for Hims & Hers is a structural pivot from a high-growth, high-margin model to a more sustainable but lower-growth platform. The catalyst was the sudden collapse of its GLP-1 weight loss drug business, which had been a key driver of explosive expansion. The stock has fallen around 70% over the past year, with a sharp ~60% decline in the last three months, as the writing appeared on the wall following FDA and patent pressures. The company had been selling compounded versions of semaglutide, but after the FDA commissioner signaled enforcement and Novo Nordisk filed a patent lawsuit, Hims & Hers was forced to stop offering the drug.

This left a critical void. The GLP-1 revenue stream, which contributed significantly to the company's 59% year-over-year revenue growth to $2.35 billion in 2025, is now effectively gone. The recent quarterly results underscore the severity of the reset. While the company beat earnings for the fourth quarter, sales growth slowed significantly, with the quarterly rate of 28% growth appearing to cut the full-year pace in half. Management's own guidance for the first quarter, projecting sales between $600 million and $625 million, misses analyst forecasts and signals the slowdown is spilling into 2026.

The strategic shift is now clear. Hims & Hers must rebuild its growth narrative on its core subscription services, which include personalized treatments for conditions like hair loss and sexual health. The company points to a monthly revenue per subscriber increase of 11% year over year to $83 and a subscriber base of over 2.5 million as foundational. Yet the math is stark: the growth engine that powered a 59% expansion is gone, leaving the company to prove it can scale its existing platform at a comparable rate. Barclays' price target cut reflects this fundamental reassessment, moving away from a valuation premised on compounded GLP-1 volume to one that must be built on the more predictable, but likely slower, cadence of a subscription health platform. The new growth story is one of resilience, not reacceleration.

Financial Impact and the Path to Sustainable Growth

The financial reset is now fully in motion. While Hims & Hers met Wall Street's revenue expectations for the fourth quarter, the guidance for the coming quarter was a clear disappointment. The company reported sales up 28.4% year on year to $617.8 million, but its revenue guidance for Q1 CY2026 is $612.5 million at the midpoint, below analyst estimates of $649 million. This miss signals a tangible slowdown in top-line momentum as the GLP-1 engine sputters out. The full-year outlook confirms the magnitude of the adjustment. Management projects 2026 revenue of $2.7 billion to $2.9 billion, a range that implies a significant deceleration from the 59% year-over-year growth to $2.35 billion in 2025.

The margin compression is the starker part of the story. The company's full-year 2026 Adjusted EBITDA guidance of $300 million to $375 million at the midpoint is notably below analyst estimates. This implies a substantial drop in profitability, likely driven by the loss of the high-margin GLP-1 business and the costs of scaling its core platform. The recent quarterly results already showed a decline, with the operating margin falling to 1.5% from 3.9% a year ago. The path to sustainable growth now hinges on the viability of the new narrative: a robust annual growth rate of approximately 21% in core U.S. revenue, driven by subscriber expansion and higher revenue per subscriber.

The foundation is there, with a subscriber base of over 2.5 million and a monthly revenue per subscriber that grew 11% year-over-year to $83. Yet the scale of the previous growth makes this new target feel like a step down. The company's own 2025 performance, with a 59% revenue growth rate, sets a high bar that the projected 21% core growth must now meet. The financial health is still solid, with a strong balance sheet and cash flow from its tenured specialties, but the trajectory has shifted from explosive expansion to a more measured, investment-heavy scaling phase. The viability of this pivot will be tested by its ability to consistently outpace the guidance range and demonstrate that the core platform can generate the kind of returns that justify its valuation in a post-GLP-1 world.

Valuation, Catalysts, and Key Risks

At a current price near $17, the stock trades at a discount to Barclays' $25 target, implying a potential 51% upside over the next year. Yet this gap reflects a fundamental reassessment, not a simple bargain hunt. The target assumes the company can successfully pivot to a sustainable growth model, but the path is fraught with execution risk. The primary catalyst for validation is clear: execution on converting its 2.5 million subscribers to higher-value, personalized products. The company points to a 55% year-over-year increase in members utilizing personalized products as a positive signal, but the broader market remains skeptical, with a Hold consensus rating from 12 analysts.

Success hinges on demonstrating that the core subscription platform can generate the kind of returns that justify its valuation in a post-GLP-1 world. The company's own projection of a robust annual growth rate of approximately 21% in core U.S. revenue is the benchmark. This requires not just subscriber growth, but a meaningful increase in revenue per subscriber through upselling and cross-selling. The recent quarterly data shows progress, with monthly revenue per subscriber rising 11% year-over-year to $83. However, the stark slowdown in overall sales growth-from a full-year 59% pace to a quarterly 28% rate-proves the scale of the challenge. The company must now prove it can consistently outpace this new, slower cadence.

The key risks to this thesis are substantial. First, the inability to replace the scale and margins of the GLP-1 business remains the central vulnerability. The company's guidance for 2026, with a projected $300 million to $375 million in Adjusted EBITDA, implies significant margin compression, likely due to the loss of that high-margin revenue stream and the costs of scaling its core platform. Second, competition in the telehealth space is intensifying, with both established players and new entrants vying for market share. The company faces heightened competition in the digital health space, which could pressure pricing and customer acquisition costs. Third, the valuation multiples still apply to the remaining growth story. Even at a discount, the stock's multiple must be supported by a credible path to the projected 21% core growth rate, a path that has yet to be fully proven.

The bottom line is that the investment case has shifted from one of explosive, compound-driven growth to one of operational execution and margin discipline. The Barclays target offers a clear, if ambitious, benchmark. The catalysts are internal-execution on the subscription model and subscriber monetization. The risks are external and structural-competition, the permanent loss of a major revenue driver, and the high bar for proving the new narrative. For now, the stock's discount to the target suggests the market is pricing in a high probability of stumble.